FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma By Ogkologos - October 7, 2026 148 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the EXCALIBER-RRMM study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... February 23, 2023 For Esophageal Cancer, Immunotherapy Likely to Play Larger Role October 19, 2020 Load more HOT NEWS Impressive Responses to PD-1 Blockade in a Large Cohort of Children... Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... Young Mom Of Two Survived Breast Cancer, Heart Failure, And Two... Long-Term Clinical Benefit with Nivolumab Plus Ipilimumab Extends Beyond Treatment Discontinuation...
